Related Experiment Videos
Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone
Constança S Cruz1, Alvaro A Cruz, Carlos A Marcílio de Souza
1Curso de Pós-graduação e Extensão em Medicina Interna da Fundação para Desenvolvimento das Ciências, Fundação Instituto Osvaldo Cruz, Salvador - Bahia, Brazil. conscruz@ig.com.br
Insights
Combining angiotensin-converting enzyme inhibitors (ACEI) with spironolactone (SLN) in severe congestive heart failure (CHF) patients significantly increases hyperkalaemia risk. Careful monitoring of potassium levels is crucial for these patients.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Severe congestive heart failure (CHF) patients benefit from angiotensin-converting enzyme inhibitors (ACEI) and spironolactone (SLN), reducing mortality.
- Concomitant use of ACEI and SLN may elevate hyperkalaemia risk in CHF patients.
Purpose of the Study:
- To evaluate the risk of hyperkalaemia in severe decompensated CHF patients treated with ACEI plus SLN compared to ACEI alone.
Main Methods:
- Retrospective cohort study of severe decompensated CHF patients (March 1999-March 2000).
- Compared patients on ACEI/SLN (n=49) versus ACEI alone (n=51).
- Assessed serum potassium and creatinine levels pre- and post-treatment; primary endpoint was hyperkalaemia (K ≥ 5.5 mEq/l).
Main Results:
- ACEI/SLN group had a higher proportion of class IV CHF.
- 16 cases of hyperkalaemia in ACEI/SLN patients vs. 1 in ACEI-only group.
- Odds ratio for hyperkalaemia was 24 for ACEI/SLN patients (14.6 when excluding class III CHF).
- Predictors included class IV CHF, increased creatinine, and diabetes.
Conclusions:
- Patients with severe decompensated CHF using ACEI with SLN face a significantly higher risk of hyperkalaemia.
- Class IV CHF, elevated creatinine, and diabetes are key predictors.
- This combination necessitates vigilant potassium monitoring.
Background:
Recent studies have shown a fall in global mortality with minimal side effects in severe congestive heart failure (CHF) patients receiving angiotensin-converting enzyme inhibitors (ACEI) plus spironolactone (SLN). However, the risk of hyperkalaemia due to ACEI may be increased by the concomitant use of SLN.
Methods:
We conducted a retrospective cohort study by examining consecutive cases of severe decompensated CHF admitted to a university hospital in Brazil from March 1999 to March 2000, which had used ACEI with or without SLN. We reviewed charts for the 30 days following admission and assessed various therapeutic regimens used for heart failure as well as serum potassium and creatinine, before and after drug exposure. The primary end-point was the development of hyperkalaemia (K > or = 5.5 mEq/l). For analysis, the subjects were split into patients treated with ACEI/SLN (n = 49) and patients treated with ACEI (n = 51) by itself.
Results:
Although demographical and clinical features were comparable between the two groups, ACEI/SLN patients had a higher proportion of class IV CHF. We found 16 cases of hyperkalaemia in ACE/SLN patients, but only one case in ACEI subjects. The odds ratio for developing hyperkalaemia in ACEI/SLN patients was 24. When class III CHF subjects were excluded, the odds ratio was 14.6 (95% confidence interval: 1.8-119.6). The best predictors of hyperkalaemia were class IV CHF, increases in creatinine following treatment and diabetes.
Conclusions:
Patients with severe decompensated CHF using ACEI with SLN are at major risk for developing hyperkalaemia.